Paper Details

  1. Home
  2. Paper Details

Leflunomide-induced pulmonary arterial hypertension: Case report and review of literature.

Author: BaldassiMara, CereserLorenzo, ColliniValentino, Di PoiEmma, DriussiMauro, GiulianaFrancesco, ImazioMassimo, NalliChiara, PatrunoVincenzo, SinagraGianfranco, StolfoDavide

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

A case report highlights the rare but serious side effect of leflunomide, a disease-modifying antirheumatic drug, in causing pulmonary arterial hypertension (PAH). Prompt discontinuation and dual combination therapy with pulmonary vasodilators led to significant improvement.
Paper Details　
Original Abstract of the Article :
Leflunomide, an isoxazole derivative, is a disease-modifying antirheumatic drug, that has successfully been used for the treatment of rheumatoid arthritis and psoriatic arthritis as a feasible alternative to methotrexate. Among side effects, pulmonary arterial hypertension (PAH) has been described i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352420/

データ提供：米国国立医学図書館（NLM）

Leflunomide and Pulmonary Arterial Hypertension: A Case Report and Review

In the realm of [rheumatoid arthritis and psoriatic arthritis] treatment, leflunomide has emerged as a valuable option. This case report explores a potential [adverse effect of leflunomide: pulmonary arterial hypertension (PAH)]. The authors describe a 55-year-old woman who developed severe PAH after taking leflunomide. This case highlights the importance of [monitoring for PAH in patients treated with leflunomide].

Leflunomide: A Potential Risk Factor for PAH

This case report raises concerns about the potential risk of PAH associated with leflunomide. It's crucial for physicians to [be aware of this potential side effect] and [monitor patients closely for signs and symptoms of PAH].

Navigating the Side Effects of Leflunomide

Patients taking leflunomide should [be aware of the potential risk of PAH]. This includes understanding the [symptoms of PAH, such as shortness of breath, chest pain, and fatigue]. Prompt diagnosis and treatment are essential if PAH develops.

Dr.Camel's Conclusion

This study, like a desert mirage, reminds us that even the most effective treatments can have unexpected side effects. It underscores the importance of careful monitoring and a proactive approach to patient care. By staying vigilant and informed, we can navigate the challenges of managing chronic conditions with greater confidence and success.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-08-13
Further Info :

Pubmed ID

35949584

DOI: Digital Object Identifier

PMC9352420

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.